NovaBay Pharmaceuticals Inc Asset Resilience Ratio
NovaBay Pharmaceuticals Inc asset resilience ratio. NovaBay Pharmaceuticals Inc (NBY) has an Asset Resilience Ratio of 66.22% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See NBY cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of NovaBay Pharmaceuticals Inc (2005–2024)
Asset resilience ratio of NovaBay Pharmaceuticals Inc from 2005 to 2024. This chart shows how NovaBay Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Read debt load of NovaBay Pharmaceuticals Inc for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down NovaBay Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see NovaBay Pharmaceuticals Inc assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $2.31 Million | 66.22% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $2.31 Million | 66.22% |
Asset Resilience Insights
- Very High Liquidity: NovaBay Pharmaceuticals Inc maintains exceptional liquid asset reserves at 66.22% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
NovaBay Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare NovaBay Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
NovaBay Pharmaceuticals Inc Asset Resilience Ratio by Year (2005–2024)
NovaBay Pharmaceuticals Inc asset resilience ratio by year from 2005 to 2024. The table below shows the annual Asset Resilience Ratio data for NovaBay Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 12.56% | $430.00K | $3.42 Million | -22.08pp |
| 2023-12-31 | 34.65% | $3.13 Million | $9.03 Million | +1.95pp |
| 2022-12-31 | 32.70% | $5.36 Million | $16.40 Million | +1.40pp |
| 2021-12-31 | 31.30% | $7.50 Million | $23.98 Million | -47.14pp |
| 2020-12-31 | 78.44% | $11.95 Million | $15.24 Million | +16.61pp |
| 2019-12-31 | 61.83% | $6.94 Million | $11.22 Million | +27.82pp |
| 2018-12-31 | 34.00% | $3.18 Million | $9.36 Million | +2.26pp |
| 2017-12-31 | 31.74% | $3.20 Million | $10.08 Million | -30.10pp |
| 2016-12-31 | 61.84% | $9.51 Million | $15.38 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $5.08 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $7.54 Million | -- |
| 2013-12-31 | 16.31% | $2.55 Million | $15.65 Million | -5.18pp |
| 2012-12-31 | 21.50% | $4.13 Million | $19.23 Million | -14.27pp |
| 2011-12-31 | 35.77% | $5.71 Million | $15.96 Million | +27.57pp |
| 2010-12-31 | 8.20% | $1.27 Million | $15.52 Million | +6.49pp |
| 2009-12-31 | 1.71% | $300.00K | $17.52 Million | -45.99pp |
| 2007-12-31 | 47.71% | $11.41 Million | $23.92 Million | -4.40pp |
| 2006-12-31 | 52.11% | $6.18 Million | $11.87 Million | +23.92pp |
| 2005-12-31 | 28.19% | $1.00 Million | $3.56 Million | -- |
About NovaBay Pharmaceuticals Inc
NovaBay Pharmaceuticals, Inc. engages in the accumulation and holding of digital assets for participation in blockchain-based networks. The company focuses on the accumulation, holding, and deployment of SKY, a protocol token of the decentralized Sky Protocol. Its services intend to support protocol-level services, including staking, governance participation, validation, and related activities. T… Read more